Kim, Su-Nam Kim, Nam Hyun Park, Yeon Sook Kim, Hanna Lee, Seokjoon Wang, Qian Kim, Yong Kee 2024-01-20T21:05:21Z 2024-01-20T21:05:21Z 2021-09-03 2009-06-15 0006-2952 https://pubs.kist.re.kr/handle/201004/132389 Microtubules are a proven target for anticancer drug development because they are critical for mitotic spindle formation and the separation of chromosomes at mitosis. We here report a novel synthetic microtubule inhibitor 7-diethylamino-3(2'-benzoxazolyl)-coumarin (DBC). DBC causes destabilization of microtubules, leading to a cell cycle arrest at G(2)/M stage. In addition, human cancer cells are more sensitive to DBC (IC50 44.8-475.2 nM) than human normal fibroblast (IC50 7.9 mu M), and DBC induces apoptotic cell death of cancer cells. Furthermore, our data show that DBC is a poor substrate of drug efflux pumps and effective against multidrug resistant (MDR) cancer cells. Taken together, these results describe a novel pharmacological property of DBC as a microtubule inhibitor, which may make it an attractive new agent for treatment of MDR cancer. (c) 2009 Elsevier Inc. All rights reserved. English PERGAMON-ELSEVIER SCIENCE LTD AURORA KINASES P-GLYCOPROTEIN AGENTS DRUGS TARGETS MITOSIS 7-Diethylamino-3(2 '-benzoxazolyl)-coumarin is a novel microtubule inhibitor with antimitotic activity in multidrug resistant cancer cells Article 10.1016/j.bcp.2009.03.007 1 BIOCHEMICAL PHARMACOLOGY, v.77, no.12, pp.1773 - 1779 BIOCHEMICAL PHARMACOLOGY 77 12 1773 1779 scie scopus 000266084600003 2-s2.0-67349212426 Pharmacology & Pharmacy Pharmacology & Pharmacy Article AURORA KINASES P-GLYCOPROTEIN AGENTS DRUGS TARGETS MITOSIS 7-Diethylamino-3(2 &apos -benzoxazolyl)-coumarin Microtubule Multidrug resistance